Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma

• Published in: International journal of hematology 2023-02, Vol.117 (2), p.216-224
• Main Authors: Jung, Jongheon, Heo, Ja Yoon, Lee, Eunyoung, Lee, Hyewon, Chang, Myung Hee, Park, Ju-Hyun, Eom, Hyeon-Seok
• Format: Article
• Language: English
• Subjects: Albumin; Albumins; C-Reactive Protein; Clinical outcomes; Hematology; Humans; Induction therapy; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma, T-Cell, Peripheral - drug therapy; Lymphoma, T-Cell, Peripheral - pathology; Malignancy; Medical prognosis; Medical records; Medicine; Medicine & Public Health; Oncology; Original Article; Patients; Prognosis; Proportional Hazards Models; Proteins; Retrospective Studies; Survival; T-cell lymphoma
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-022-03474-x

Purpose Peripheral T-cell lymphoma (PTCL) is an aggressive and heterogenous T-cell lymphoid malignancy. The prognostic value of C-reactive protein-to-albumin ratio (CAR) has never been assessed in PTCL. Materials and methods This study retrospectively reviewed the medical records of 76 patients diagnosed with various subtypes of PTCL. A CAR cutoff value of 0.794 was determined, and clinical outcomes, including response rate, overall survival (OS), and progression-free survival (PFS), were compared between the high (> 0.794) and low (≤ 0.794) CAR groups. Results After induction therapy, complete response was achieved in 8 (32.0%) and 39 patients (76.5%) in the high and low CAR groups, respectively. During the median follow-up of 57.5 months, the high CAR group had significantly worse 5-year PFS and 5-year OS rates. Even with adjustment for the International Prognostic Index (≥ 3), Prognostic Index for PTCL-unspecified (≥ 3), and T cell score (≥ 2), high CAR remained a significant prognostic factor for PFS (hazard ratio [HR]: 4.01, 95% confidence interval [CI] 2.04–7.86, p